Economics and quality of life after acute myocardial infarction: Insights from GUSTO-I

Journal of Thrombosis and Thrombolysis

Volumn 3, Issue 2, 1996, Pages 151-155

  Mark, Daniel B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Economics; Myocardial infarction; Thromblytic therapy

Indexed keywords

HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEART MUSCLE REPERFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

EID: 0029883088     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00132408     Document Type: Article

References (21)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
2. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
3. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave-front phenomenon of ischemic cell death: Myocardial infarct size versus duration of coronary occlusion in dogs. Circulation 1977;56:786-794.
4. Rentrop KP, Feit F, Blanke H, et al. Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. N Engl J Med 1984;311: 1457-1463.
5. Kennedy JW, Ritchie JL, Davis KB, et al. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983;309: 1477-1482.
6. Simoons ML, Vos J, Tijssen JPG, et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989;14:1609-1615.
7. Gruppo Italiano per Lo Studio Della Streptochinasi, Nell'Infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:349-360.
8. ISIS-2 (Second International Study of Infarct Survival): Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
9. Califf RM, Topol EJ. The paradigm of acute reperfusion and the GUSTO I trial. In: Califf RM, Mark DB, Wagner GS, eds. Acute Coronary Care. St. Louis, Mo: Mosby-Year Book, 1995, pp. 69-83.
10. The TIMI Study Group. The thrombosis in myocardial infarction trial: Phase I findings. N Engl J Med 1985;312:932.
11. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;2:526-530.
12. Gruppo Italiano per Lo Studio Della Sopravvivenza, Nell'Infarcto Miocardico: GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
13. ISIS-3 Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
14. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329-673-682.
15. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329: 1615-1622.
16. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-1424.
17. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Inter Med 1990:113:147-154.
18. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia: WB Saunders, 1980.
19. Mark DB. Medical economics and health policy issues for interventional cardiology. In: Topol EJ, (ed). Textbook of Interventional Cardiology. Philadelphia: WB Saunders, 1993, pp. 1323-1353.
20. Anonymous. 1994 Drug Topics Red Book. Montvale, NJ: Medical Economics Data, 1994.
21. Naylor CD, Bronskill S, Goel V. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. Can J Cardiol 1993;9:553-558.